Intestinal Failure Oral Nutrition Market

How big is Intestinal Failure Oral Nutrition Market in 2026?

USD 160.7 Million in 2026 and USD 322.1 Million by 2036 at a 7.2% CAGR.

The intestinal failure oral nutrition market is valued at USD 160.7 Million in 2026, against USD 149.9 Million in 2025. FMI forecasts USD 322.1 Million by 2036, representing a 7.2% CAGR over the forecast period. Patients who can tolerate more oral intake may still need carefully selected nutrition and fluid support. The UK Specialist Pharmacy Service’s 2024 guidance on St Mark’s solution explains why hydration in short bowel syndrome needs a specific formulation. Nutritional supplements and oral rehydration products serve different purposes. Dietitians and pharmacists assess the patient’s absorption, fluid losses and tolerance before planning continued use at home.

In the USA, reimbursement for oral products can be a practical barrier after discharge. UK prescribing follows specialist hydration and nutrition protocols. Germany emphasizes individualized treatment, while Japanese product information draws attention to tolerability in short bowel states. South Korean clinical reports show the continuing support needed around home parenteral nutrition. Across these systems, a reduction in intravenous support depends on the patient’s condition; commercial availability alone does not establish suitability.

Key Takeaways

• Patients moving toward oral intake may still need specialist nutrition and hydration support.
• Elemental / Semi-Elemental ONS accounts for 42.4% of product revenue in 2026. These formulas offer options when digestion or absorption is impaired, with selection directed by the clinical team.
• Short Bowel Syndrome represents 50.3% of indication revenue in 2026. Reduced functional bowel length can create continuing needs for nutritional and fluid support.
• PN-Weaning holds 48.0% of use-stage revenue in 2026. Oral products may become more important as a patient tolerates a reduction in intravenous support.
• Homecare accounts for 46.9% of setting revenue in 2026. Long-term use depends on a tolerable product and a supply arrangement the household can maintain.
• Hospital Pharmacy represents 36.5% of channel revenue in 2026. Specialist assessment and formulary access often establish which product continues after discharge.
• Opportunity: Protocolized home nutrition bundles that align elemental or peptide ONS with oral rehydration and modular nutrients during PN-weaning.
• Companies include Danone Nutricia (Elemental 028), Nestle Health Science, Abbott, Ajinomoto Cambrooke, Kate Farms, Fresenius Kabi, B. Braun.

Analyst Perspective

"The formula needs to fit a specific stage of rehabilitation. Tolerance and practical use at home matter alongside nutrient composition when the care team considers changes to intravenous support."

- Anurag Sharma, Principal Consultant, Future Market Insights

How is the intestinal failure oral nutrition market segmented?

The market is segmented by Product Type, Etiology, PN Dependence, End User, and Sales Channel.

By Product Type: Elemental / Semi-Elemental ONS, Oral Rehydration Solutions, Modular Nutrients (MCT / Glucose Polymers), Others; By Etiology: Short Bowel Syndrome, Motility Disorders, Mucosal Disease, Others; By PN Dependence: PN-Weaning, Partial PN + Oral, Fully Oral / Enteral; By End User: Homecare, Intestinal Rehab Centers, Hospitals, Others; By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online, Institutional Tender, Others.

Why does homecare lead demand within the end user category?

Homecare concentrates repeat use because intestinal failure is frequently managed over long periods after acute stabilization. Products need to fit routines that patients and caregivers can execute outside a specialist center. That favors ready-to-drink supplements, powders with clear preparation requirements, and oral rehydration protocols that can be repeated every day. Homecare also changes the supplier task. Clinical suitability must be matched with delivery continuity and patient education. The 2025 South Korean home parenteral nutrition study shows how long-term care can extend well beyond the hospital and depends on coordinated nutrition support. Oral products that support tolerated feeding during rehabilitation can therefore follow the patient across the home phase rather than remain limited to inpatient episodes. Home access to medical nutrition must remain consistent with the clinical plan and the patient’s ability to use the product.

• Homecare accounts for 46.9% of 2026 revenue because long-duration management moves repeat nutrition use into patient and caregiver routines.
• In 2025, the South Korean pediatric home-PN study described multidisciplinary nutrition support and long-duration home management, reinforcing the need for coordinated products and follow-up outside inpatient care.

Why do elemental / semi-elemental ONS lead demand within the product type category?

Elemental and semi-elemental formulas reduce the digestive work required before nutrients can be absorbed. This matters when bowel length is reduced or mucosal function is compromised. Product design commonly uses free amino acids or hydrolyzed peptides and may include medium-chain triglycerides to support absorption. Nutricia describes Elemental 028 Extra Liquid as an amino-acid-based formula that is prescribable in the UK for short bowel syndrome and intractable malabsorption. Nestle Health Science positions Peptamen around malabsorption and maldigestion with hydrolyzed whey protein and MCT. These features make the category clinically distinct from standard oral supplements and support selection when intact-protein formulas are not the preferred starting point. Selection among oral clinical supplements depends on the patient’s nutritional needs and tolerance.

• Elemental / Semi-Elemental ONS accounts for 42.4% of 2026 revenue because formula architecture directly addresses impaired digestion and absorption.
• In 2026, Nutricia still lists Elemental 028 for gastrointestinal impairment. Nestle Health Science and Abbott also maintain oral-capable peptide formulas for impaired gastrointestinal function.

Why does short bowel syndrome lead demand within the etiology category?

Short bowel syndrome creates a direct link between anatomy and oral nutrition need. Reduced absorptive surface can produce high fluid losses and poor uptake of macronutrients or electrolytes. The Specialist Pharmacy Service states that people with short bowel syndrome often require fluid, electrolyte, and nutrient supplementation. It also notes that oral rehydration can help even when some patients still need parenteral nutrition or intravenous fluids. This combination supports recurring demand for products that solve different parts of the problem. Oral rehydration manages sodium and water balance. Elemental or peptide formulas provide an option when digestion and absorption remain constrained. The resulting need is specific to absorption and hydration, rather than general malnutrition alone. Short bowel care requires clinical nutrition planning around anatomy, absorption and hydration.

• Short Bowel Syndrome represents 50.3% of 2026 revenue because reduced bowel length produces persistent hydration and absorption requirements.
• In January 2024, the UK Specialist Pharmacy Service published specific short bowel guidance for St Mark’s solution and set a sodium concentration threshold for effective absorption.

Why does PN-weaning lead demand within the PN dependence category?

PN-weaning is the point where oral nutrition has its clearest economic and clinical role. Intestinal rehabilitation aims to increase tolerated oral or enteral intake while reducing intravenous supplementation when adaptation permits. The 2023 ESPEN guideline on chronic intestinal failure frames care as a multidisciplinary process that includes nutrition support and individualized management. South Korean pediatric evidence published in 2025 adds an operational view. In that cohort, several patients who discontinued home parenteral nutrition did so after they could tolerate feeding. Oral products are not a simple substitute for PN. They become relevant when absorption, hydration, and intake are stable enough for clinicians to lower intravenous dependence without compromising nutrition status. Changes in parenteral nutrition remain a specialist clinical decision during any transition toward oral intake.

• PN-Weaning holds 48.0% of 2026 revenue because oral products become more important as patients move toward lower intravenous support.
• In September 2025, a Seoul National University Children’s Hospital study reported that six of 40 pediatric home-PN patients were weaned and four of those six tolerated feeding sufficiently to discontinue PN.

Why does hospital pharmacy lead demand within the sales channel category?

Hospital pharmacies sit close to the clinical decision that determines whether a specialized formula is appropriate. Intestinal failure products are often selected with input from gastroenterologists, dietitians, and pharmacists because hydration risk and formula tolerance are patient-specific. This favors channels that can support prescription workflows and institutional review. Company distribution strategies also reinforce hospital access. In April 2024, Nestlé Health Science announced a joint venture with Dr. Reddy’s in India that included Peptamen and Resource brands. The venture combined specialized nutrition brands with a broad retail and distribution network. Hospital specification can establish the initial product, with subsequent supplies delivered through retail or home channels. Pharmacy teams may handle enteral nutrition alongside oral products, while maintaining the distinction between routes of administration.

• Hospital Pharmacy represents 36.5% of 2026 revenue because specialist evaluation and formulary access often precede ongoing oral use.
• In April 2024, Nestlé Health Science included Peptamen and Resource products in its India joint venture with Dr. Reddy’s to expand access through established healthcare distribution.

What are the drivers, restraints and opportunities in the Intestinal Failure Oral Nutrition Market?

Demand rises as rehabilitation teams reduce parenteral support while maintaining hydration, while tolerance and reimbursement restrict uptake and home-based nutrition protocols create a scalable opportunity.

• Driver: Clinical pressure to reduce parenteral support while maintaining hydration and nutrient absorption.
• Restraint: Patient-specific tolerance, fluid-balance risk, and incomplete coverage for orally administered medical nutrition.
• Opportunity: Protocolized home nutrition bundles that align elemental or peptide ONS with oral rehydration and modular nutrients during PN-weaning.

Rehabilitation aims to increase enteral or oral autonomy where the patient’s condition permits. Chronic intestinal failure care is designed around the amount of intravenous supplementation that remains necessary. When intestinal adaptation permits a reduction, clinicians need oral options that maintain energy intake and hydration. The 2023 ESPEN guideline emphasizes individualized multidisciplinary management for chronic intestinal failure. UK guidance published in 2024 adds a practical hydration requirement by specifying high-sodium oral rehydration for short bowel states. This combination shifts buying toward products that solve a defined physiological problem. It also creates repeat demand because the transition can extend over months rather than a single hospital episode.

Clinical suitability does not guarantee coverage or sustained tolerance. In the USA, the current CMS enteral nutrition policy states that orally administered enteral products are non-covered under the Medicare Part B prosthetic-device benefit. That rule does not eliminate demand, but it can move cost to another payer or to the patient. Clinical tolerance creates a second barrier. High-output patients can worsen diarrhea if fluid composition is inappropriate. Taste and preparation burden can also erode adherence. Product selection must fit the absorptive condition, with a practical arrangement for ongoing payment and supply.

Coordinated supply can make a prescribed home nutrition plan easier to follow. Where clinicians consider it appropriate, elemental or peptide ONS can be supplied alongside oral rehydration and modular nutrients during PN reduction. Hospital pharmacy selection and dependable home delivery can maintain the chosen products after discharge. Pharmacist or digital instruction can explain preparation without changing the prescription. Any benefit from such a service depends on patient tolerance, clinical monitoring and an affordable route to continued supply.

Which country CAGRs are profiled in the Intestinal Failure Oral Nutrition Market?

Country	CAGR (2026 to 2036)
USA	6.9%
UK	6.3%
Germany	5.9%
Japan	5.2%
South Korea	7.4%

How do country-level CAGRs compare in the intestinal failure oral nutrition market?

South Korea has the highest forecast CAGR at 7.4%, followed by the USA at 6.9%, the UK at 6.3% and Germany at 5.9%. Japan is forecast at 5.2%, giving a 2.2 percentage-point range over 2026 to 2036. Specialist care and reimbursement arrangements differ across these countries. A faster rate may accompany developing care pathways, while a mature system can have substantial demand at a lower growth rate.

• USA: CMS excludes orally administered enteral products from the Medicare Part B prosthetic-device benefit. A clinical recommendation may therefore leave a payment gap that the hospital and patient must resolve before continuing use at home.
• UK: Specialist Pharmacy Service guidance updated in June 2024 explains the role of St Mark’s electrolyte solution in intestinal failure. Accurate preparation and appropriate counseling are important when care moves from hospital to the community.
• Germany: The DGEM S3 guideline addresses nutrition and fluid management according to remaining bowel function. Suppliers need product information that lets specialists assess the individual patient’s requirements.
• Japan: PMDA’s Ensure Liquid information includes a short-bowel-related diarrhea precaution. That product-specific warning demonstrates why tolerance and formula choice must be reviewed by the care team.
• South Korea: A 2025 Seoul National University Children’s Hospital study described the practical demands of pediatric home parenteral nutrition. Oral transition requires specialist follow-up and dependable home support, alongside clinical tolerance.

Regional coverage includes North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.

Country-wise Analysis

• USA: Demand for Intestinal Failure Oral Nutrition in the USA is forecast to rise at 6.9% CAGR from 2026 to 2036. CMS policy is a defining local constraint because its enteral nutrition article states that orally administered enteral products are non-covered under the Medicare Part B prosthetic-device benefit. Clinical recommendation can therefore leave an unresolved payment question. Hospital pharmacy coordination, payer-specific support and direct fulfillment can help maintain supply after discharge.
• UK: A 6.3% CAGR is forecast for the UK between 2026 and 2036. The Specialist Pharmacy Service published St Mark’s electrolyte solution guidance in January 2024 and updated it in June 2024. It specifies at least 90 mmol/L sodium for effective absorption in short bowel states. Palatability and accurate preparation affect continued use. Counseling materials need to reflect the formulation and fit NHS prescribing and community pharmacy practice.
• Germany: Demand for Intestinal Failure Oral Nutrition in Germany is forecast to increase at 5.9% CAGR from 2026 to 2036. The German Society for Nutritional Medicine S3 guideline on short bowel syndrome and intestinal failure sets out the role of nutrition therapy and fluid management. It also emphasizes individualized care because patients vary substantially. Patient variation limits a single standard formula offer. Evidence must address the relevant malabsorption or hydration requirement and be available to the specialists directing prescription-led use.
• Japan: Japan is forecast to expand at 5.2% CAGR from 2026 to 2036. The Japanese package information for Ensure Liquid, published by the Pharmaceuticals and Medical Devices Agency, identifies diarrhea risk in patients with short-bowel syndrome or other severe functional bowel disorders. This product-specific precaution illustrates the need to match formula selection with the patient’s clinical condition. The care team needs product-specific information and reliable access to the selected formulation.
• South Korea: Demand for Intestinal Failure Oral Nutrition in South Korea is forecast to rise at 7.4% CAGR from 2026 to 2036. A September 2025 Seoul National University Children’s Hospital study described 40 pediatric home-PN patients and found that six were weaned from HPN. The authors also identified logistical and system-support needs around long-term care. Home delivery and system support matter alongside clinical tolerance. Specialist teams retain responsibility for transition protocols and for determining when oral intake can support a reduction in intravenous dependence.

Who are the notable companies in the intestinal failure oral nutrition market?

Danone Nutricia (Elemental 028), Nestle Health Science, Abbott, Ajinomoto Cambrooke, Kate Farms, Fresenius Kabi, B. Braun.

Danone Nutricia (Elemental 028), Nestle Health Science and Abbott offer elemental or peptide products for impaired digestion or absorption. Competition depends on the suitability of the formula and access through the clinical channels that select it.

• Danone Nutricia (Elemental 028), Nestle Health Science, and Abbott: gastrointestinal formula depth with amino-acid or peptide approaches that address malabsorption and impaired GI function.
• Ajinomoto Cambrooke and Kate Farms: differentiated specialty nutrition formats with amino-acid or plant-based peptide positioning and growing direct-use relevance.
• Fresenius Kabi and B. Braun bring broader clinical-nutrition platforms that connect hospital procurement with transitions between parenteral, enteral and oral support where clinically appropriate.

Competitive Benchmarking: Intestinal Failure Oral Nutrition Market

Company	Specialized GI formulas	Oral-use options	Clinical nutrition support	Geographic reach
Danone Nutricia (Elemental 028)	High	High	High	Europe and international specialized-nutrition markets
Nestle Health Science	High	High	High	International medical-nutrition markets
Abbott	High	High	High	International nutrition markets
Ajinomoto Cambrooke	Medium	High	High	USA and selected international markets
Kate Farms	Medium	High	High	USA-led medical-nutrition distribution
Fresenius Kabi	High	High	High	Europe and international clinical-nutrition markets
B. Braun	Medium	Medium	High	International hospital-nutrition markets

Scoring basis: High for Specialized GI formulas covers several elemental, peptide or malabsorption-oriented products; Medium marks a narrower family. High for Oral-use options covers products intended for oral use in multiple preparation or presentation choices; Medium marks a more limited route. High for Clinical nutrition support combines professional product information with established clinical-nutrition supply; Medium covers narrower support. Unscored indicates that the relevant offer is not part of the company’s stated portfolio. Ratings do not imply clinical superiority or suitability for an individual patient.

Nutricia's Elemental 028 powder and liquid provide an elemental route. Peptide formulas and general oral supplements from other suppliers require indication-specific review and are not interchangeable with oral rehydration solution. Kate Farms became part of Danone in 2025 and is represented within that current ownership context.

Key Developments in the Intestinal Failure Oral Nutrition Market

• In February 2025, Kate Farms introduced Pediatric Peptide 1.0 in an organic strawberry flavor. The company described the formula as suitable for children with impaired gastrointestinal function and for drinking or tube feeding. The launch added a palatable oral option to a peptide-based medical nutrition line. Its market relevance lies in adherence and format choice because long-duration gastrointestinal nutrition requires products that patients can tolerate repeatedly after discharge.
• In July 2025, Danone completed the acquisition of a majority stake in Kate Farms. Danone linked the business with its existing medical nutrition portfolio that includes Nutricia. The company also described access across hospitals and home channels as well as online and retail routes. The transaction broadened Danone’s specialized nutrition platform in North America. It also connected Danone Nutricia (Elemental 028) with a plant-based peptide portfolio and a different set of healthcare purchasing relationships.
• In March 2026, Fresenius Kabi expanded its plant-based clinical nutrition range in Great Britain. The company highlighted Fresubin PLANT-BASED Drink as an established oral nutritional supplement while introducing a related tube-feed format. The oral drink adds format choice for patients who need medical nutrition and prefer plant-based protein. For the intestinal failure oral market, the development shows how broader clinical nutrition suppliers can extend oral portfolios while maintaining continuity with institutional nutrition pathways.

Key Players in the Intestinal Failure Oral Nutrition Market

Elemental and Peptide Gastrointestinal Nutrition

• Danone Nutricia (Elemental 028)
• Nestle Health Science
• Abbott

Alternative and Home-Oriented Medical Nutrition

• Ajinomoto Cambrooke
• Kate Farms

Integrated Clinical Nutrition Platforms

• Fresenius Kabi
• B. Braun

Intestinal Failure Oral Nutrition Market - Report Scope

Coverage field	Report scope
Market breakdown	Product Type; Etiology; PN Dependence; End User; Sales Channel; Region
Quantitative Units	USD Million
Market Definition	Revenue includes sales of oral nutrition products used in intestinal failure within the stated product type, etiology, PN dependence, end-user, and sales-channel classifications. It excludes parenteral nutrition, tube-feeding-only products, drugs, surgical care, intestinal rehabilitation service fees, and general nutrition products not used for intestinal failure.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	USA, UK, Germany, Japan, South Korea
Key Companies Profiled	Danone Nutricia (Elemental 028), Nestle Health Science, Abbott, Ajinomoto Cambrooke, Kate Farms, Fresenius Kabi, B. Braun
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down sizing using product-level demand indicators, clinical utilization patterns, channel evidence, company disclosures, country operating conditions, and forecast reconciliation.

Intestinal Failure Oral Nutrition Market - Research Methodology

Method	Approach
Primary Research	FMI primary research engages manufacturers, distributors, clinical nutrition specialists, hospital procurement teams, pharmacists, and end users. Discussion topics include product selection, purchase triggers, channel economics, reimbursement, tolerance requirements, and adoption constraints.
Desk Research	FMI reviews regulator and health-system policies, clinical guidelines, peer-reviewed literature, company filings, first-party product material, public procurement information, and other authoritative records.
Market Sizing and Forecasting	Market sizing combines product and channel indicators with the eligible intestinal-failure population, patterns of PN dependence, oral nutrition use, clinical pathway changes, and country access conditions. Forecast assumptions consider rehabilitation practice, reimbursement, homecare penetration, product availability, and competitive activity.
Data Validation	FMI cross-checks quantitative and qualitative findings across independent source types and reconciles country, segment, and company evidence. Validation excludes double counting, parenteral nutrition revenue, tube-feeding-only revenue, and adjacent products that fall outside the market definition.

Intestinal Failure Oral Nutrition Market by Segments

Intestinal Failure Oral Nutrition Market segmented by Product Type:

• Elemental / Semi-Elemental ONS
• Oral Rehydration Solutions
• Modular Nutrients (MCT / Glucose Polymers)
• Others

Intestinal Failure Oral Nutrition Market segmented by Etiology:

• Short Bowel Syndrome
• Motility Disorders
• Mucosal Disease
• Others

Intestinal Failure Oral Nutrition Market segmented by PN Dependence:

• PN-Weaning
• Partial PN + Oral
• Fully Oral / Enteral

Intestinal Failure Oral Nutrition Market segmented by End User:

• Homecare
• Intestinal Rehab Centers
• Hospitals
• Others

Intestinal Failure Oral Nutrition Market segmented by Sales Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Institutional Tender
• Others

Intestinal Failure Oral Nutrition Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Pironi, L. et al. (2023). ESPEN guideline on chronic intestinal failure in adults - Update 2023.
• Specialist Pharmacy Service (2024, January 31). Using St Mark’s electrolyte solution.
• Centers for Medicare & Medicaid Services (2023, October 1). Enteral Nutrition - Policy Article A58833, revision effective date.
• Lamprecht, G. et al. (2014). S3 Guideline of the German Society for Nutritional Medicine: Short bowel syndrome and intestinal failure.
• Hwang, J. H. et al. (2025, September 25). A single-center experience of home parenteral nutrition for pediatric intestinal failure.
• Nutricia (2026, accessed August 18). Elemental 028 Extra Liquid.
• Nestlé Health Science (2024, April 25). Nestlé Health Science and Dr. Reddy’s to form joint venture in India.
• Abbott Nutrition (2026, accessed August 18). Vital 1.5 Cal.
• Fresenius Kabi (2026, March 18). Innovating in PLANT-BASED Nutrition.
• Ajinomoto Cambrooke (2025, June 24). Cambrooke celebrates 25 years of innovation and a bold mission.
• Kate Farms (2025, February 19). Kate Farms introduces Pediatric Peptide 1.0 in an organic natural strawberry flavor.
• B. Braun (2026, accessed August 18). Nutricomp Drink Plus HP.
• Danone (2025, July 1). Danone completes acquisition of a majority stake in Kate Farms.
• Pharmaceuticals and Medical Devices Agency, Japan. (n.d.). Ensure Liquid: English prescribing information. Accessed September 9, 2026.
• Nutricia (n.d.; accessed September 9, 2026). Elemental 028 Extra Powder and Elemental 028 Extra Liquid product information.

This Report Answers

• Which clinical and operating pressures support demand for intestinal failure oral nutrition?
• Why does Elemental / Semi-Elemental ONS hold the leading Product Type position?
• How does Short Bowel Syndrome influence downstream oral nutrition demand?
• Why does PN-Weaning hold the leading PN Dependence position?
• How do growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies have direct products and market-relevant capabilities in this market?
• How do reimbursement, tolerance, and fluid-balance requirements limit adoption?
• What should clinical nutrition and procurement decision-makers evaluate before purchasing?